A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

Media formats available:

The real residual risk in patients with CVD & diabetes: The promise of epigenetics
The real residual risk in patients with CVD & diabetes: The promise of epigenetics
LDL-c: Done Deal, Next Epigenetics?
The real residual risk in patients with CVD & diabetes: The promise of epigenetics
- Prof. Erik Stroes, MD
Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
LDL-c: Done Deal, Next Epigenetics?
Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
- Jorge Plutzky, MD

PACE-CME